CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-05 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Sale 10b5-1 | −10,000 | $63.38 | $634K | 79,944 |
| 2026-03-05 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −3,989 | $63.38 | $253K | 2,737 |
| 2026-02-19 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −588 | $68.54 | $40K | 107,643 |
| 2026-02-19 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,629 | $69.82 | $114K | 106,014 |
| 2026-02-19 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −212 | $68.54 | $15K | 105,802 |
| 2026-02-19 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −590 | $69.82 | $41K | 105,212 |
| 2026-02-18 | Gravier Pierre CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,992 | $69.36 | $208K | 87,318 |
| 2026-02-18 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −7,371 | $69.36 | $511K | 387,082 |
| 2026-02-18 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −2,494 | $69.36 | $173K | 70,199 |
| 2026-02-18 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,484 | $69.36 | $172K | 89,944 |
| 2026-02-18 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −3,056 | $69.36 | $212K | 112,140 |
| 2026-02-18 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −65 | $69.36 | $5K | 6,726 |
| 2026-02-18 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −3,019 | $69.36 | $209K | 77,122 |
| 2026-02-18 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −3,081 | $69.36 | $214K | 108,231 |
| 2026-02-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,813 | $25.69 | $72K | 114,125 |
| 2026-02-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −2,811 | $69.29 | $195K | 111,314 |
| 2026-02-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −2 | $70.13 | $140 | 111,312 |
| 2026-02-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,813 | 22,501 | ||
| 2026-01-12 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −1,024 | $78.70 | $81K | 80,141 |
| 2026-01-09 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,521 | $77.46 | $118K | 112,105 |
Page 9 of 25 · 493 trades